Bibliography
- Kontoghiorghes GJ. A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Expert Opin Drug Saf 2013;12(5):605-9
- Pocock N. CHMP finalises review of deaths associated with deferasirox (Exjade®) in the US and updates to the SPC. Reference: October 2009 Plenary meeting monthly report Source: EMEA. 2009. Available from: http://www.nelm.nhs.uk
- Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects. Curr Med Chem. 2004;11:2161-83
- Tefler P, Goen PG, Christou S et al. Survival of medically treated thalassaemia patients in Cyprus. Trends and risk factors over the period 1980 – 2004. Haematologica 2006;91:1187-92
- Kolnagou A, Kontoghiorghes GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron stores. Br J Haematol. 2010;150:489-90